Publications by authors named "Marina Onda"
The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real-world clinical study. Our study aimed to identify predictive factors for responders to deucravacitinib.
View Article and Find Full Text PDFArticle Synopsis
- Tralokinumab, a human monoclonal antibody, is an approved treatment for atopic dermatitis (AD) and was evaluated for its effectiveness and safety in Japanese patients between October 2023 and March 2024.
- In a study involving 103 patients, significant improvements in eczema severity were observed at weeks 4 and 12, including notable reductions in the Eczema Area and Severity Index (EASI) scores and itch intensity.
- The treatment was generally well-tolerated, with mild and manageable side effects reported in 14.8% of patients, including a low incidence of conjunctivitis that resolved on its own.
Article Synopsis
- Tralokinumab, an anti-IL-13 antibody, is an approved treatment for atopic dermatitis (AD), but real-world data on its efficacy and safety is limited.
- A study involving 104 patients assessed the real-world effectiveness and safety of tralokinumab over 24 weeks, revealing that treatment was more effective in therapy-naïve patients compared to those with prior systemic therapy.
- Treatment led to significant improvements in clinical and laboratory measures of AD, with a notable decrease in inflammatory markers and mild adverse events occurring in 27.9% of patients.
Article Synopsis
- * Bimekizumab is a treatment that targets specific proteins (IL-17A and IL-17F) involved in inflammation and is evaluated for effectiveness in treating psoriasis in a study of 52 patients over 24 weeks.
- * The results showed that bimekizumab significantly improved lesions in these difficult areas, with high success rates in clearing symptoms and enhancing patients’ overall quality of life by the end of the study.
Article Synopsis
- Psoriasis is a tough chronic skin condition that can heavily affect patients' quality of life, especially in areas like the genitals, nails, and scalp.
- A study examining the effects of deucravacitinib, a new oral medication that targets TYK2, involved 70 psoriasis patients over several weeks, focusing on improvement in specific health assessments.
- Results showed that deucravacitinib significantly helped reduce lesions in hard-to-treat areas and improved overall quality of life for those with psoriasis.